Serum Institute Fracas Exposes Loose Ends of India s Clinical Trial Machinery
Participants voices are missing from deliberations about how officials should address serious adverse events in clinical trials.
Representative photo: NCI/Unsplash.
Health11/Dec/2020
Bengaluru: In November, two leading Indian COVID-19 vaccine manufacturers, Bharat Biotech and Serum Institute of India (SII), found themselves embroiled in controversy. Media reports alleged that there had been a “serious adverse event” in phase 1 of Bharat Biotech’s clinical trials for Covaxin. Phase 1 tests the safety of a new drug or vaccine in human subjects for the first time.
Then, a 40-year-old man in Chennai, through a legal notice to SII, sought compensation of Rs 5 crore for an illness he alleged appeared after he participated in a clinical trial for Covishield, SII-made version of University of Oxford and AstraZeneca’s COVID-19 vaccine candidate.
Serum Institute vaccine volunteer not ready to withdraw legal notice
freepressjournal.in - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from freepressjournal.in Daily Mail and Mail on Sunday newspapers.
Serum Institute vax volunteer not ready to withdraw legal notice
business-standard.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from business-standard.com Daily Mail and Mail on Sunday newspapers.